迪哲医药(688192.SH)：高瑞哲和 Birelentinib 最新研究数据在第67届美国临床血液学会（ASH）发布

Core Viewpoint - The company, DIZH Medical (688192.SH), announced significant advancements in two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, focusing on treatments for T-cell and B-cell lymphomas [1] Group 1: Drug Developments - The high-selectivity JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made multiple new progressions in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has presented the latest clinical data for the treatment of B-cell lymphoma [1]